"{\"info\":{\"nct_id\":\"NCT00050349\",\"official_title\":\"EPO906 Therapy in Patients With Metastatic Carcinoid Tumors and Other Neuroendocrine Tumors\",\"criteria\":\"Inclusion Criteria:\\n\\n* Patients with biopsy-proven metastatic carcinoid tumors or other neuroendocrine tumors (Islet cell, Gastrinomas and VIPomas) with at least one measurable lesion (other than bone) that has either not been previously irradiated or if previously irradiated has demonstrated progression since the radiation therapy\\n* The patient has no major impairment of renal or hepatic function, as defined by the following laboratory parameters: total bilirubin \\\\<1.5 X ULN; AST, ALT\\\\<2.5X ULN (\\\\<5 X ULN if liver metastases are present)\\n* Patients on Sandostatin Lar (long acting somatostatin analogue) must be on a stable dose for 30 days prior to study entry and short acting somatostatin analogues must be judged to be on a clinically stable dose by the investigator prior to study entry\\n* Must have a life expectancy of greater than three (3) months\\n* Karnofsky Performance Status \\\\> 60\\n* Female patients must have a negative serum pregnancy test at screening. (Not applicable to patients with bilateral oophorectomy and/or hysterectomy or to those patients who are postmenopausal.)\\n\\nExclusion Criteria:\\n\\n* Patients with symptomatic CNS metastases or leptomeningeal involvement\\n* Patients with known brain metastases, unless these metastases have been treated and/or have been stable for at least six months prior to study start. Subjects with a history of brain metastases must have a head CT with contrast to document either response or progression.\\n* Patients with bone metastases as the only site(s) of measurable disease\\n* Patients with hepatic artery chemoembolization within the last 6 months (one month if there are other sites of measurable disease)\\n* Patients who have been previously treated with radioactive directed therapies\\n* Patients who have been previously treated with epothilone\\n* Patients with any peripheral neuropathy or unresolved diarrhea greater than Grade 1\\n* Patients with severe cardiac insufficiency patients taking Coumadin or other warfarin-containing agents with the exception of low dose warfarin (1 mg or less) for the maintenance of in-dwelling lines or ports\\n* Patients taking any experimental therapies history of another malignancy within 5 years prior to study entry except curatively treated non-melanoma skin cancer, prostate cancer, or cervical cancer in situ\\n* Patients with active or suspected acute or chronic uncontrolled infection including abcesses or fistulae\\n* Patients with a medical or psychiatric illness that would preclude study or informed consent and/or history of noncompliance to medical regimens or inability or unwillingness to return for all scheduled visits\\n* HIV+ patients\\n* Pregnant or lactating females.\"},\"atomic_criteria\":[{\"raw_text\":\"biopsy-proven metastatic carcinoid tumors\",\"paraphrased_text\":\"Patients must have biopsy-proven metastatic carcinoid tumors.\"},{\"raw_text\":\"other neuroendocrine tumors (Islet cell, Gastrinomas and VIPomas)\",\"paraphrased_text\":\"Patients must have other neuroendocrine tumors such as Islet cell tumors, Gastrinomas, or VIPomas.\"},{\"raw_text\":\"at least one measurable lesion (other than bone)\",\"paraphrased_text\":\"Patients must have at least one measurable lesion that is not in the bone.\"},{\"raw_text\":\"that has either not been previously irradiated\",\"paraphrased_text\":\"The measurable lesion must not have been previously irradiated.\"},{\"raw_text\":\"if previously irradiated has demonstrated progression since the radiation therapy\",\"paraphrased_text\":\"If the measurable lesion was previously irradiated, it must have shown progression since the radiation therapy.\"},{\"raw_text\":\"Patients on Sandostatin Lar (long acting somatostatin analogue) must be on a stable dose for 30 days prior to study entry\",\"paraphrased_text\":\"Patients must be on a stable dose of Sandostatin Lar for 30 days before entering the study.\"},{\"raw_text\":\"short acting somatostatin analogues must be judged to be on a clinically stable dose by the investigator prior to study entry\",\"paraphrased_text\":\"Short acting somatostatin analogues must be on a clinically stable dose as judged by the investigator before study entry.\"},{\"raw_text\":\"Must have a life expectancy of greater than three (3) months\",\"paraphrased_text\":\"The patient must have a life expectancy of more than three months.\"},{\"raw_text\":\"Patients with symptomatic CNS metastases\",\"paraphrased_text\":\"Patients must have symptomatic CNS metastases.\"},{\"raw_text\":\"leptomeningeal involvement\",\"paraphrased_text\":\"Patients must have leptomeningeal involvement.\"},{\"raw_text\":\"Patients with bone metastases as the only site(s) of measurable disease\",\"paraphrased_text\":\"Patients must have bone metastases as the only site of measurable disease.\"},{\"raw_text\":\"Patients with hepatic artery chemoembolization within the last 6 months\",\"paraphrased_text\":\"Patients must have undergone hepatic artery chemoembolization within the last 6 months.\"},{\"raw_text\":\"one month if there are other sites of measurable disease\",\"paraphrased_text\":\"Patients must have undergone hepatic artery chemoembolization within the last month if there are other sites of measurable disease.\"},{\"raw_text\":\"Patients who have been previously treated with radioactive directed therapies\",\"paraphrased_text\":\"Patients must have received radioactive directed therapies in the past.\"},{\"raw_text\":\"Patients who have been previously treated with epothilone\",\"paraphrased_text\":\"Patients must have received prior treatment with epothilone.\"},{\"raw_text\":\"Patients with any peripheral neuropathy\",\"paraphrased_text\":\"Patients must not have any peripheral neuropathy.\"},{\"raw_text\":\"unresolved diarrhea greater than Grade 1\",\"paraphrased_text\":\"Patients must not have unresolved diarrhea greater than Grade 1.\"},{\"raw_text\":\"Patients with severe cardiac insufficiency\",\"paraphrased_text\":\"Patients must have severe cardiac insufficiency.\"},{\"raw_text\":\"patients taking Coumadin or other warfarin-containing agents\",\"paraphrased_text\":\"Patients must be taking Coumadin or other warfarin-containing agents.\"},{\"raw_text\":\"with the exception of low dose warfarin (1 mg or less) for the maintenance of in-dwelling lines or ports\",\"paraphrased_text\":\"Patients taking low dose warfarin (1 mg or less) for the maintenance of in-dwelling lines or ports are an exception.\"},{\"raw_text\":\"active or suspected acute or chronic uncontrolled infection\",\"paraphrased_text\":\"Patients must not have an active or suspected acute or chronic uncontrolled infection.\"},{\"raw_text\":\"abcesses\",\"paraphrased_text\":\"Patients must not have abscesses.\"},{\"raw_text\":\"fistulae\",\"paraphrased_text\":\"Patients must not have fistulae.\"},{\"raw_text\":\"Patients with a medical or psychiatric illness that would preclude study or informed consent\",\"paraphrased_text\":\"Patients must not have a medical or psychiatric illness that would prevent them from participating in the study or giving informed consent.\"},{\"raw_text\":\"history of noncompliance to medical regimens\",\"paraphrased_text\":\"Patients must not have a history of noncompliance with medical regimens.\"},{\"raw_text\":\"inability or unwillingness to return for all scheduled visits\",\"paraphrased_text\":\"Patients must be able and willing to return for all scheduled visits.\"},{\"raw_text\":\"HIV+ patients\",\"paraphrased_text\":\"Patients must be HIV positive.\"}],\"leftovers\":[\"Inclusion Criteria:\",\"* Patients with \",\" or \",\" with \",\" \",\" or \",\"* \",\" and \",\"* \",\"Exclusion Criteria:\",\"* \",\" or \",\"* \",\"* \",\" (\",\")\",\"* \",\"* \",\"* \",\" or \",\"* \",\" \",\" \",\"* Patients with \",\" including \",\" or \",\"* \",\" and/or \",\" or \",\"* \"]}"